Hematopoietic stem cell engineering at a crossroads.

The genetic engineering of hematopoietic stem cells is the basis for potentially treating a large array of hereditary and acquired diseases, and stands as the paradigm for stem cell engineering in general. Recent clinical reports support the formidable promise of this approach but also highlight the limitations of the technologies used to date, which have on occasion resulted in clonal expansion, myelodysplasia, or leukemogenesis. New research directions, predicated on improved vector designs, targeted gene delivery or the therapeutic use of pluripotent stem cells, herald the advent of safer and more effective hematopoietic stem cell therapies that may transform medical practice. In this review, we place these recent advances in perspective, emphasizing the solutions emerging from a wave of new technologies and highlighting the challenges that lie ahead.

[1]  Yang Xu,et al.  Modeling disease in human ESCs using an efficient BAC-based homologous recombination system. , 2010, Cell stem cell.

[2]  D. Persons.  The challenge of obtaining therapeutic levels of genetically modified hematopoietic stem cells in β‐thalassemia patients , 2010, Annals of the New York Academy of Sciences.

[3]  T. Enver,et al.  Forcing cells to change lineages , 2009, Nature.

[4]  Hojun Li,et al.  In vivo genome editing restores hemostasis in a mouse model of hemophilia , 2011, Nature.

[5]  Alexander Meissner,et al.  Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. , 2010, Cell stem cell.

[6]  Kathryn L. Parsley,et al.  Long-Term Persistence of a Polyclonal T Cell Repertoire After Gene Therapy for X-Linked Severe Combined Immunodeficiency , 2011, Science Translational Medicine.

[7]  R. Mulligan,et al.  Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[8]  C. D. de Graaf,et al.  The Lmo2 Oncogene Initiates Leukemia in Mice by Inducing Thymocyte Self-Renewal , 2010, Science.

[9]  F. Gage,et al.  In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector , 1996, Science.

[10]  P. Kantoff,et al.  Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[11]  A. Fischer,et al.  Reversal of early neurologic and neuroradiologic manifestations of X-linked adrenoleukodystrophy by bone marrow transplantation. , 1990, The New England journal of medicine.

[12]  Bruce Aronow,et al.  Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy. , 2007, The Journal of clinical investigation.

[13]  F. Bushman,et al.  Retroviral DNA Integration: ASLV, HIV, and MLV Show Distinct Target Site Preferences , 2004, PLoS biology.

[14]  A. Rimek,et al.  High-level ectopic HOXB4 expression confers a profound in vivo competitive growth advantage on human cord blood CD34+ cells, but impairs lymphomyeloid differentiation. , 2003, Blood.

[15]  Dana Carroll,et al.  Gene targeting using zinc finger nucleases , 2005, Nature Biotechnology.

[16]  M. Blasco,et al.  The Ink4/Arf locus is a barrier for iPS cell reprogramming , 2009, Nature.

[17]  M. Sadelain,et al.  The genetic engineering of hematopoietic stem cells: the rise of lentiviral vectors, the conundrum of the ltr, and the promise of lineage-restricted vectors. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[18]  A. Miller,et al.  Improved retroviral vectors for gene transfer and expression. , 1989, BioTechniques.

[19]  H. Kiem,et al.  Efficient transduction and engraftment of G-CSF-mobilized peripheral blood CD34+ cells in nonhuman primates using GALV-pseudotyped gammaretroviral vectors. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[20]  C. von Kalle,et al.  Lentivirus-mediated reprogramming of somatic cells in the absence of transgenic transcription factors. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[21]  H. Heslop,et al.  An inducible caspase 9 safety switch for T-cell therapy. , 2005, Blood.

[22]  C. von Kalle,et al.  Insertion sites in engrafted cells cluster within a limited repertoire of genomic areas after gammaretroviral vector gene therapy. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  T. Enver,et al.  Impaired embryonic haematopoiesis yet normal arterial development in the absence of the Notch ligand Jagged1 , 2008, The EMBO journal.

[24]  E. Medico,et al.  Promoter trapping reveals significant differences in integration site selection between MLV and HIV vectors in primary hematopoietic cells. , 2005, Blood.

[25]  Shinya Yamanaka,et al.  Immunogenicity of induced pluripotent stem cells. , 2011, Circulation research.

[26]  A. Schambach,et al.  Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[27]  Donald B Kohn,et al.  Update on gene therapy for immunodeficiencies. , 2010, Clinical immunology.

[28]  M. Mcclure,et al.  Progress and prospects: Foamy virus vectors enter a new age , 2010, Gene Therapy.

[29]  D. Heim,et al.  Hematopoietic stem cell gene therapy: towards clinically significant gene transfer efficiency , 2000, Immunological reviews.

[30]  Shoshannah L. Roth,et al.  A method to sequence and quantify DNA integration for monitoring outcome in gene therapy , 2011, Nucleic acids research.

[31]  Shin-Ichi Nishikawa,et al.  Continuous single-cell imaging of blood generation from haemogenic endothelium , 2009, Nature.

[32]  Michel Sadelain,et al.  Safe harbours for the integration of new DNA in the human genome , 2011, Nature Reviews Cancer.

[33]  P. Glazer,et al.  Triplex forming oligonucleotides: sequence-specific tools for gene targeting. , 2001, Human molecular genetics.

[34]  Daniel G. Miller,et al.  Comparison of HIV-derived lentiviral and MLV-based gammaretroviral vector integration sites in primate repopulating cells. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[35]  E. Kirkness,et al.  Somatic coding mutations in human induced pluripotent stem cells , 2011, Nature.

[36]  E. Bouhassira,et al.  Gene Specificity of Suppression of Transgene-Mediated Insertional Transcriptional Activation by the Chicken HS4 Insulator , 2009, PloS one.

[37]  A. Nienhuis,et al.  An experimental system for the evaluation of retroviral vector design to diminish the risk for proto-oncogene activation. , 2008, Blood.

[38]  Russell J. Taylor,et al.  Bioluminescent Imaging Demonstrates That Transplanted Human Embryonic Stem Cell‐Derived CD34+ Cells Preferentially Develop into Endothelial Cells , 2009, Stem cells.

[39]  D. Clapp,et al.  Cell cycle-related changes in repopulating capacity of human mobilized peripheral blood CD34(+) cells in non-obese diabetic/severe combined immune-deficient mice. , 1998, Blood.

[40]  R. Nagel,et al.  Correction of Sickle Cell Disease in Transgenic Mouse Models by Gene Therapy , 2001, Science.

[41]  P. Glazer,et al.  Nanoparticles deliver triplex-forming PNAs for site-specific genomic recombination in CD34+ human hematopoietic progenitors. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[42]  Sridhar Hannenhalli,et al.  Genome-wide analysis of retroviral DNA integration , 2005, Nature Reviews Microbiology.

[43]  Michel Sadelain,et al.  Therapeutic haemoglobin synthesis in β-thalassaemic mice expressing lentivirus-encoded human β-globin , 2000, Nature.

[44]  Frédéric Pâques,et al.  Meganucleases and DNA double-strand break-induced recombination: perspectives for gene therapy. , 2007, Current gene therapy.

[45]  B. Palmer,et al.  Safety and Efficacy of a Lentiviral Vector Containing Three Anti-HIV Genes-CCR5 Ribozyme, Tat-rev siRNA, and TAR Decoy-in SCID-hu Mouse-Derived T Cells. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[46]  T. Ichisaka,et al.  Suppression of induced pluripotent stem cell generation by the p53–p21 pathway , 2009, Nature.

[47]  S. Orkin,et al.  The emergence of hematopoietic stem cells is initiated in the placental vasculature in the absence of circulation. , 2008, Cell stem cell.

[48]  M. Sadelain.  Eliminating cells gone astray. , 2011, The New England journal of medicine.

[49]  David A. Williams,et al.  Finding the needle in the hay stack: hematopoietic stem cells in Fanconi anemia. , 2009, Mutation research.

[50]  D. Kohn,et al.  Gene therapy fulfilling its promise. , 2009, The New England journal of medicine.

[51]  M. Sadelain,et al.  Stem cell engineering for the treatment of severe hemoglobinopathies. , 2008, Current molecular medicine.

[52]  Yoav Mayshar,et al.  Identification and classification of chromosomal aberrations in human induced pluripotent stem cells. , 2010, Cell stem cell.

[53]  Bin Zhang,et al.  IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers. , 2008, The Journal of clinical investigation.

[54]  Riitta Lahesmaa,et al.  Copy number variation and selection during reprogramming to pluripotency , 2011, Nature.

[55]  C. Dunbar,et al.  Contributions of gene marking to cell and gene therapies. , 2011, Human gene therapy.

[56]  G. Gahrton,et al.  TK.007: A novel, codon-optimized HSVtk(A168H) mutant for suicide gene therapy. , 2010, Human gene therapy.

[57]  B. Wood,et al.  High incidence of leukemia in large animals after stem cell gene therapy with a HOXB4-expressing retroviral vector. , 2008, The Journal of clinical investigation.

[58]  K. Ikeda,et al.  3'UTR-truncated Hmga2 cDNA causes MPN-like hematopoiesis by conferring a clonal growth advantage at the level of HSC in mice. , 2011, Blood.

[59]  C. von Kalle,et al.  Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis. , 2005, Blood.

[60]  Irving L. Weissman,et al.  Tracking single hematopoietic stem cells in vivo using high-throughput sequencing in conjunction with viral genetic barcoding , 2011, Nature Biotechnology.

[61]  T. Wolfsberg,et al.  Reduced genotoxicity of avian sarcoma leukosis virus vectors in rhesus long-term repopulating cells compared to standard murine retrovirus vectors. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[62]  John J Rossi,et al.  Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[63]  K. Kissa,et al.  Blood stem cells emerge from aortic endothelium by a novel type of cell transition , 2010, Nature.

[64]  Julie V. Harness,et al.  Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. , 2011, Cell stem cell.

[65]  S. Yamanaka.  Strategies and new developments in the generation of patient-specific pluripotent stem cells. , 2007, Cell stem cell.

[66]  C. von Kalle,et al.  Acute myeloid leukemia is associated with retroviral gene transfer to hematopoietic progenitor cells in a rhesus macaque. , 2006, Blood.

[67]  F. Bushman,et al.  Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. , 2008, The Journal of clinical investigation.

[68]  K. Sugamura,et al.  gamma-c gene transfer into SCID X1 patients' B-cell lines restores normal high-affinity interleukin-2 receptor expression and function. , 1996, Blood.

[69]  B. Aronow,et al.  Clonality analysis after retroviral-mediated gene transfer to CD34+ cells from the cord blood of ADA-deficient SCID neonates , 2003, Nature Medicine.

[70]  A. Consiglio,et al.  Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells , 2009, Nature.

[71]  Hans Martin,et al.  Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease , 2010, Nature Medicine.

[72]  D. Russell,et al.  Transduction of hematopoietic cells by foamy virus vectors. , 1996, Blood.

[73]  T. Shimada,et al.  Optimized lentiviral vector design improves titer and transgene expression of vectors containing the chicken beta-globin locus HS4 insulator element. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[74]  P. Andrews,et al.  Culture and characterization of human embryonic stem cells. , 2004, Stem cells and development.

[75]  Christof von Kalle,et al.  The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. , 2009, The Journal of clinical investigation.

[76]  G. Daley,et al.  Correction of a Genetic Defect by Nuclear Transplantation and Combined Cell and Gene Therapy , 2002, Cell.

[77]  Shawn M. Burgess,et al.  Transcription Start Regions in the Human Genome Are Favored Targets for MLV Integration , 2003, Science.

[78]  Hans-Peter Kiem,et al.  Foamy virus vector integration sites in normal human cells , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[79]  Jean A. Roayaei,et al.  Sustained high-level polyclonal hematopoietic marking and transgene expression 4 years after autologous transplantation of rhesus macaques with SIV lentiviral vector-transduced CD34+ cells. , 2009, Blood.

[80]  N. Copeland,et al.  Insertional Mutagenesis Identifies Genes That Promote the Immortalization/Self-Renewal of Primary Bone Marrow Progenitor Cells. , 2005 .

[81]  Luca Biasco,et al.  Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy. , 2007, The Journal of clinical investigation.

[82]  S. Yamanaka,et al.  Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors , 2006, Cell.

[83]  C. Baum,et al.  The genomic risk of somatic gene therapy. , 2010, Seminars in cancer biology.

[84]  A. Schnerch,et al.  Direct conversion of human fibroblasts to multilineage blood progenitors , 2010, Nature.

[85]  David R. Liu,et al.  Revealing Off-Target Cleavage Specificities of Zinc Finger Nucleases by In Vitro Selection , 2011, Nature Methods.

[86]  D. Kohn.  Gene therapy for genetic haematological disorders and immunodeficiencies , 2001, Journal of internal medicine.

[87]  C. Dunbar,et al.  Avoidance of stimulation improves engraftment of cultured and retrovirally transduced hematopoietic cells in primates. , 2001, The Journal of clinical investigation.

[88]  C. L. Li,et al.  Genomic and functional assays demonstrate reduced gammaretroviral vector genotoxicity associated with use of the cHS4 chromatin insulator. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[89]  Manuel Serrano,et al.  A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity , 2009, Nature.

[90]  A. Nienhuis,et al.  Genotoxicity of retroviral integration in hematopoietic cells. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[91]  M. Stojkovic,et al.  Efficient hematopoietic differentiation of human embryonic stem cells on stromal cells derived from hematopoietic niches. , 2008, Cell stem cell.

[92]  Jérôme Larghero,et al.  Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia , 2010, Nature.

[93]  Christine Kinnon,et al.  Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo. , 2007, The Journal of clinical investigation.

[94]  A. Ciuffi.  Mechanisms governing lentivirus integration site selection. , 2008, Current gene therapy.

[95]  Paul Shinn,et al.  HIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots , 2002, Cell.

[96]  Michel Sadelain,et al.  Genomic safe harbors permit high β-globin transgene expression in thalassemia induced pluripotent stem cells , 2011, Nature Biotechnology.

[97]  Adrian P Gee,et al.  Inducible apoptosis as a safety switch for adoptive cell therapy. , 2011, The New England journal of medicine.

[98]  K. van Besien,et al.  Granulocyte colony-stimulating factor-based stem cell mobilization in patients with sickle cell disease. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[99]  Prashant Mali,et al.  Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells. , 2009, Cell stem cell.

[100]  P. Malik,et al.  Mechanism of reduction in titers from lentivirus vectors carrying large inserts in the 3'LTR. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[101]  Christof von Kalle,et al.  Stem-cell gene therapy for the Wiskott-Aldrich syndrome. , 2010, The New England journal of medicine.

[102]  A. Thrasher,et al.  Progress and prospects: gene therapy for inherited immunodeficiencies , 2009, Gene Therapy.

[103]  Kathryn L. Parsley,et al.  Hematopoietic Stem Cell Gene Therapy for Adenosine Deaminase–Deficient Severe Combined Immunodeficiency Leads to Long-Term Immunological Recovery and Metabolic Correction , 2011, Science Translational Medicine.

[104]  K. Schwarz,et al.  Zinc-finger nuclease-induced gene repair with oligodeoxynucleotides: wanted and unwanted target locus modifications. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[105]  Marius Wernig,et al.  Treatment of Sickle Cell Anemia Mouse Model with iPS Cells Generated from Autologous Skin , 2007, Science.

[106]  Jeffrey C. Miller,et al.  An unbiased genome-wide analysis of zinc-finger nuclease specificity , 2011, Nature Biotechnology.

[107]  Vanessa Taupin,et al.  Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo , 2010, Nature Biotechnology.

[108]  S. Rivella,et al.  Genetic treatment of severe hemoglobinopathies: the combat against transgene variegation and transgene silencing. , 1998, Seminars in hematology.

[109]  D. W. Emery.  The use of chromatin insulators to improve the expression and safety of integrating gene transfer vectors. , 2011, Human gene therapy.

[110]  Cameron S. Osborne,et al.  LMO2-Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1 , 2003, Science.

[111]  Christine Kinnon,et al.  Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. , 2008, The Journal of clinical investigation.

[112]  Michael S. Becker,et al.  Fate tracing reveals the endothelial origin of hematopoietic stem cells. , 2008, Cell stem cell.

[113]  Brian E. McIntosh,et al.  Genetic correction and analysis of induced pluripotent stem cells from a patient with gyrate atrophy , 2011, Proceedings of the National Academy of Sciences.

[114]  P. Gregory,et al.  Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery , 2007, Nature Biotechnology.

[115]  Jens Boch,et al.  TALEs of genome targeting , 2011, Nature Biotechnology.

[116]  Christof von Kalle,et al.  A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. , 2003, The New England journal of medicine.

[117]  Yang Du,et al.  Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1 , 2006, Nature Medicine.

[118]  Christof von Kalle,et al.  Distinct Genomic Integration of MLV and SIV Vectors in Primate Hematopoietic Stem and Progenitor Cells , 2004, PLoS biology.

[119]  Keiichiro Suzuki,et al.  Highly efficient transient gene expression and gene targeting in primate embryonic stem cells with helper-dependent adenoviral vectors , 2008, Proceedings of the National Academy of Sciences.

[120]  Christian Schuetz,et al.  Regeneration and orthotopic transplantation of a bioartificial lung , 2010, Nature Medicine.

[121]  L. Zon,et al.  Hematopoiesis: An Evolving Paradigm for Stem Cell Biology , 2008, Cell.

[122]  P. Andrews,et al.  Adaptation to culture of human embryonic stem cells and oncogenesis in vivo , 2007, Nature Biotechnology.

[123]  J. Dick,et al.  Generation of hematopoietic repopulating cells from human embryonic stem cells independent of ectopic HOXB4 expression , 2005, The Journal of experimental medicine.

[124]  W. Ostertag,et al.  FMEV vectors: both retroviral long terminal repeat and leader are important for high expression in transduced hematopoietic cells , 1998, Gene Therapy.

[125]  N. Galjart,et al.  In vivo imaging of haematopoietic cells emerging from the mouse aortic endothelium , 2010, Nature.

[126]  C. Dunbar,et al.  Gene transfer to hematopoietic stem cells: implications for gene therapy of human disease. , 1996, Annual review of medicine.

[127]  Gianluigi Zanetti,et al.  Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection. , 2011, Blood.

[128]  Christine Kinnon,et al.  Mutations in TNFRSF13B Encoding TACI Are Associated With Common Variable Immunodeficiency in Humans , 2006, Pediatrics.

[129]  B. Fehse,et al.  Clonal Dominance of Hematopoietic Stem Cells Triggered by Retroviral Gene Marking , 2005, Science.

[130]  T. Bestor.  Gene silencing as a threat to the success of gene therapy. , 2000, The Journal of clinical investigation.

[131]  R. Ghirlando,et al.  Chromatin boundaries, insulators, and long-range interactions in the nucleus. , 2010, Cold Spring Harbor symposia on quantitative biology.

[132]  Christof von Kalle,et al.  and insertional genotoxicity Cell culture assays reveal the importance of retroviral vector design for , 2006 .

[133]  Luigi Naldini,et al.  Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications , 2009, Nature Reviews Genetics.

[134]  James M. Allen,et al.  Successful treatment of canine leukocyte adhesion deficiency by foamy virus vectors , 2008, Nature Medicine.

[135]  J. Ellis.  Silencing and variegation of gammaretrovirus and lentivirus vectors. , 2005, Human gene therapy.

[136]  S. Rivella,et al.  Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin. , 2000, Nature.

[137]  R. Nagel,et al.  Permanent and panerythroid correction of murine β thalassemia by multiple lentiviral integration in hematopoietic stem cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[138]  Anitha Rao,et al.  RNA-Based Gene Therapy for HIV with Lentiviral Vector–Modified CD34+ Cells in Patients Undergoing Transplantation for AIDS-Related Lymphoma , 2010, Science Translational Medicine.

[139]  Manfred Schmidt,et al.  Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy , 2009, Science.

[140]  C. von Kalle,et al.  Recurrent retroviral vector integration at the Mds1/Evi1 locus in nonhuman primate hematopoietic cells. , 2005, Blood.

[141]  Angelique M. Nelson,et al.  Engineering of human pluripotent stem cells by AAV-mediated gene targeting. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[142]  Michel Sadelain,et al.  Occurrence of leukaemia following gene therapy of X-linked SCID , 2003, Nature Reviews Cancer.

[143]  J. Ihle,et al.  Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients , 1993, The Lancet.

[144]  R. Humphries,et al.  Effects of HOXB4 Overexpression on Ex Vivo Expansion and Immortalization of Hematopoietic Cells from Different Species , 2007, Stem cells.

[145]  M. Jasin,et al.  Genetic manipulation of genomes with rare-cutting endonucleases. , 1996, Trends in genetics : TIG.